Table 1 |
|
|
Clinical and demographic features of the study population |
|
| Variable |
PsA patients (n = 100) |
|
|
|
| Gender ratio (M/F) |
55/45 |
| Mean age (years) |
52 ± 14 |
| Psoriasis duration (years) |
24 ± 9 |
| Arthritis duration (years) |
22 ± 8 |
| Psoriasis onset age (years) |
26 ± 14 |
| Arthritis onset age (years) |
35 ± 12 |
| Psoriasis–arthritis latency (years) |
8 ± 7 |
| Psoriasis before arthritis (%) |
75 |
| Axial pattern (%) |
35 |
| Oligoarthritis (%) |
40 |
| Polyarthritis (%) |
25 |
| DIP disease (%) |
40 |
| Mutilans form (%) |
4 |
| Onychopathy (%) |
45 |
| Erosive disease (%) |
44 |
| Enthesitis (%) |
35 |
| Uveitis (%) |
17 |
| ESR |
36 ± 12 |
| RF (%)a |
7 |
| ANA (%)a |
10 |
|
|
|
|
ANA, antinuclear antibodies; DIP, distal interphalangeal joint; ESR, erythrocyte sedimentation rate; PsA, psoriatic arthritis; RF, rheumatoid factor. Errors are shown as SD. aNone of these patients had rheumatoid arthritis or systemic lupus erythematosus. |
|
|
Queiro et al. Arthritis Research & Therapy 2006 8:R185 doi:10.1186/ar2097 |
|
